Hospital
Brunswick Community Hospital, LLC
Brunswick Community Hospital, LLC was paid $15.04M by Medicaid between Jan 2018 and Dec 2024, across 92 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoBRUNSWICK COMMUNITY HOSPITAL, LLC
BOLIVIA, NC 28422
BOLIVIA, NC 28422
33aNPI1710915756assigned 06/29/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.04M
24GClaims299,438
24DCodes billed92
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#38 of 92
Median peer was paid$11.47M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,603 | $1.40M | |
| 2019 | 40,824 | $1.45M | |
| 2020 | 46,074 | $953K | |
| 2021 | 35,545 | $2.08M | |
| 2022 | 42,379 | $3.07M | |
| 2023 | 48,110 | $2.98M | |
| 2024incomplete | 47,903 | $3.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 19,021 | 16,278 | $4.43M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 30,467 | 26,786 | $4.18M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.6% | 4,399 | 3,744 | $1.30M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 8.1% | 7,318 | 6,780 | $1.21M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.3% | 7,387 | 6,739 | $494K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.1% | 10,258 | 8,794 | $468K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 853 | 796 | $467K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 6,107 | 5,112 | $263K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 10,167 | 8,395 | $197K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.3% | 7,249 | 6,379 | $191K |
| 80053 | Comprehensive metabolic panel | 1.2% | 20,303 | 17,243 | $177K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 22,308 | 19,006 | $171K |
80 more codes
| 71045 | Radiologic examination, chest; single view | 1.1% | 6,333 | $171K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 1,063 | $160K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,478 | $117K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 645 | $90K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,627 | $81K |
| J3490 | Unclassified drugs | <1% | 62,340 | $75K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,954 | $54K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,441 | $52K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,178 | $48K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 720 | $45K |
| 81025 | <1% | 5,886 | $42K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,126 | $40K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 223 | $39K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,418 | $39K |
| 87430 | <1% | 2,697 | $37K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,380 | $35K |
| D0272 | Bitewings - two radiographic images | <1% | 175 | $30K |
| 83735 | <1% | 4,762 | $28K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 465 | $28K |
| 87070 | <1% | 2,440 | $24K | |
| 83690 | <1% | 3,676 | $23K | |
| 81001 | <1% | 5,551 | $19K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 246 | $16K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 590 | $16K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 95 | $15K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,140 | $15K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 927 | $14K |
| 84484 | <1% | 1,696 | $13K | |
| 81003 | <1% | 4,313 | $11K | |
| 84703 | <1% | 1,035 | $10K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 151 | $10K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 349 | $10K |
| J2704 | Injection, propofol, 10 mg | <1% | 475 | $8K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 56 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 607 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 96 | $5K |
| D1351 | Sealant - per tooth | <1% | 40 | $5K |
| D1120 | Dental cleaning, child | <1% | 37 | $5K |
| 87631 | <1% | 85 | $4K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 26 | $4K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 34 | $4K |
| 80299 | <1% | 238 | $4K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 12 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 147 | $3K |
| D1206 | Topical application of fluoride varnish | <1% | 26 | $3K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 20 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 134 | $2K |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 121 | $2K |
| 94060 | <1% | 65 | $2K | |
| 94729 | <1% | 64 | $2K | |
| 85027 | <1% | 141 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 59 | $890.85 |
| 94726 | <1% | 63 | $832.30 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 36 | $807.80 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 28 | $797.95 |
| 74018 | <1% | 25 | $681.72 | |
| 80143 | <1% | 112 | $675.67 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 25 | $672.32 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 35 | $587.62 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 28 | $550.06 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $366.72 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,465 | $356.73 |
| 80061 | Lipid panel | <1% | 13 | $288.10 |
| 85379 | <1% | 26 | $273.28 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 17 | $258.26 |
| 85610 | <1% | 75 | $255.08 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 36 | $230.16 |
| 82550 | <1% | 45 | $211.53 | |
| 80179 | <1% | 112 | $174.14 | |
| 87420 | <1% | 12 | $171.36 | |
| 83880 | <1% | 13 | $169.20 | |
| 80076 | <1% | 13 | $141.80 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 2,604 | $101.66 |
| 87186 | <1% | 13 | $98.70 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 17 | $32.09 |
| 87486 | <1% | 17 | $32.09 | |
| 87581 | <1% | 17 | $32.09 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 38 | $2.60 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 87 | $1.41 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 14 | $0.69 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKING, HEATHER (PRESIDENT & COO NHBMC)
| Provider | Location | Paid |
|---|---|---|
| Panhandle Therapy Center LLC | Blountstown, FL | $3.44M |
| Brunswick Community Hospital, LLC | Bolivia, NC | $49K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.